on POP Biotechnologies, Inc.
POP Biotechnologies Announces Positive Interim Results for COVID-19 Vaccine Trial
BUFFALO, NY / ACCESSWIRE / September 27, 2024 / POP Biotechnologies (POP BIO), a biopharmaceutical company based in Buffalo, NY, has announced positive interim results for its Phase 3 trial of EuCorVac-19, a COVID-19 vaccine developed in partnership with South Korea's EuBiologics. The study, published in the Journal of Medical Virology, highlights the vaccine's safety and immunogenicity.
The trial, conducted in the Philippines with 2,600 participants, compared EuCorVac-19 (ECV-19) to the COVISHIELD™ vaccine. Results show that ECV-19 produced higher levels of neutralizing antibodies and fewer mild side effects after the first dose. Developed using POP BIO's spontaneous nanoliposome antigen particle (POP BIO SNAP™) technology, ECV-19 targets the receptor binding domain of SARS-CoV-2.
Lead author Jonathan Lovell noted, "ECV-19 elicited a strong immune response against both the Wuhan strain and the Omicron variant." EuBiologics plans to register the vaccine in the Philippines and explore new vaccine developments for other diseases.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all POP Biotechnologies, Inc. news